Cart
sales@molnova.com
MC 2494
CAS No. ——
MC 2494( MC2494 )
Catalog No. M17073 CAS No. ——
MC 2494 is a nove potent, pan-Sirtuin (SirT) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMC 2494
-
NoteResearch use only, not for human use.
-
Brief DescriptionMC 2494 is a nove potent, pan-Sirtuin (SirT) inhibitor.
-
DescriptionMC 2494 is a nove potent, pan-Sirtuin (SirT) inhibitor, increases RIP1 acetylation in the death domain and induces bona fide tumour-restricted acetylated RIP1/caspase-8-mediated apoptosis; displays tumour-selective potential in vitro, in leukemic blasts ex vivo, and in vivo in both xenograft and allograft cancer models; also displays tumour-preventive activity by blocking DMBA-induced mammary gland hyper-proliferation in vivo.
-
In Vitro——
-
In Vivo——
-
SynonymsMC2494
-
PathwayChromatin/Epigenetic
-
TargetSirtuin
-
RecptorSirtuin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight426.86
-
Molecular FormulaC24H15ClN4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(E)-3-(4-(2-chlorobenzoyl)-1H-pyrrol-2-yl)-2-cyano-N-(quinolin-5-yl)acrylamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Altucci L, et al. Clin Cancer Res. 2018 Mar 13. pii: clincanres.3081.2017.
molnova catalog
related products
-
EX 527 (Selisistat)
EX 527 is a potent and selective SIRT1 inhibitor with IC50 of 38 nM, exhibits >200-fold selectivity against SIRT2 and SIRT3.
-
BML-278
BML-278 is a SIRT1 activator with an EC150 of 1 μM. It increases H3K9 methylation and inhibits H3K9 acetylation in parental and maternal prokaryotes, improving early embryonic development.
-
Pristimerin
Pristimerin has anticancer activity, treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells.
